CTT Pharmaceutical Holdings, Inc. (Formerly, "Mindesta Inc.")
Consolidated Balance Sheets (unaudited)
(Expressed in United States Dollars, unless otherwise stated)

	As at March 31, 2016 $ (note 1) (unaudited)	As at December 31, 2015 $ (note 1) (unaudited)
Assets		
Current		
Cash	(570)	969
Prepaid expenses (note 3)	398,335	637,218
Receivables	5,430	5,430
Total current assets	403,195	643,617
Prepaid expenses (note 3)	—	—
Total assets	403,195	643,617
Liabilities		
Current		
Accounts payable and accrued liabilities	245,042	221,402
Due to related parties (note 5)	88,032	87,082
Total liabilities	333,074	308,484
Stockholders' equity		
Common stock 300,000,000 shares authorized, $0.0001 par value; 21,319,302 shares issued and outstanding (2015 – 21,319,302)	2,132	2,132
Additional paid-in capital	1,951,798	1,951,798
Common shares to be issued (note 3)	40,000	40,000
Contributed surplus	649,318	649,318
Accumulated other comprehensive income (loss)	2,831	5,127
Deficit	(2,575,958)	(2,313,242)
Total stockholders' equity	70,121	335,133
Total liabilities and stockholders' equity	403,195	643,617

See accompanying notes to unaudited interim condensed consolidated financial statements

On October 16, 2015, the Company effectuated a 1 for 10 reverse stock split. Shares have been retroactively restated.

Approved by Board

(signed) Dean Hanisch
Director

CTT Pharmaceutical Holdings, Inc. (Formerly, "Mindesta Inc.")
Consolidated Statements of Operations and Comprehensive Loss (unaudited)
(Expressed in United States Dollars, unless otherwise stated)

	3 months ended March 31	
	2016	**2015**
	$ (note 1) (unaudited)	**$** (note 1) (unaudited)
Operating expenses		
Consulting fees	125,905	168,059
Investor relations	123,286	124,269
Marketing and promotion	-	1,006
Professional fees	12,330	8,836
General and administration	1,195	34,882
	262,716	337,052
Other **items**		
Gain on contracts settled through shares	-	-
Net (loss)	(262,716)	(337,052)
Other Comprehensive income (loss)		
Foreign currency translation	-	3,370
Comprehensive income (loss)	(262,716)	(333,682)
Weighted average number of common shares outstanding – basic and diluted (note 4)	21,319,302	19,506,802
Net (loss) per share – basic and diluted	(0.01)	(0.02)

See accompanying notes to unaudited condensed interim financial statements

On October 16, 2015, the Company effectuated a 1 for 10 reverse stock split. Shares have been retroactively restated

CTT Pharmaceutical Holdings, Inc. (Formerly, "Mindesta Inc.")
Consolidated Statements of Cash Flows (unaudited)
(Expressed in United States Dollars, unless otherwise stated)

	3 months ended March 31	
	2016	**2015**
	$ (note 1) (unaudited)	**$** (note 1) (unaudited)
Cash provided by (used in) Operating activities		
Net (loss) attributable to the company	(262,716)	(337,052)
Stock based compensation	-	43,650
Shares issued for services	238,883	235,788
Imputed interest on amounts due to related party	-	4,306
Changes in non-cash operating working capital:		
Accounts payable and accrued liabilities	23,640	13,656
	(193)	(39,652)
Financing activities		
Proceeds from (payment to) related party	-	28,550
	-	28,550
Investing activities		
Cash received pursuant to reverse acquisition	—	-
	—	-
Foreign exchange rate effect on cash	(1,346)	3,370
Net increase in cash	(1,539)	(7,732)
Cash, beginning of period	969	81,179
Cash, end of period	(570)	73,447
Supplementary information		
Interest paid	—	—
Income taxes paid	—	—

See accompanying notes to unaudited interim condensed consolidated financial statements

CTT Pharmaceutical Holdings, Inc. (Formerly, "Mindesta Inc.")
Statement of Stockholders' Equity (unaudited)
For the Period Ended March 31, 2016
(Unaudited)

	Common Stock		Additional		Common		Accumulated Other	Total
	Number of Shares	Amount	Paid-in Capital	Contributed Surplus	shares to be issued	Accumulated Deficit	Comprehensive Income (loss)	Stockholders' Deficit
Balance at December 31, 2012	14,918,329	1,492	82,708	77,665	—	(176,289)	(5,576)	(20,000)
Contribution of capital - interest	—	—	—	3,828	—	—	—	3,828
Contribution of capital – loan forgiveness (Note 4)	—	—	—	4,352	—	—	—	4,352
Foreign currency translation adjustment	—	—	—	—	—	—	1,409	1,409
Net loss	—	—	—	—	—	(18,911)	—	(18,911)
Balance at December 31, 2013	14,918,329	1,492	82,708	85,845	—	(195,200)	(4,167)	(29,322)
Issued pursuant to Exchange Agreement (note 2)	4,588,474	459	63,021	—	—	—	—	63,480
Stock based compensation	—	—	—	308,439		—	—	308,439
Common shares to be issued (Note 3)	—	—	—	—	1,806,250	—	—	1,806,250
Contribution of capital – interest	—	—	—	7,958	—	—	—	7,958
Contribution of capital – loan forgiveness (Note 4)	—	—	—	5,139	—	—	—	5,139
Foreign currency translation adjustment	—	—	—	—	—	—	3,098	3,098
Net income	—	—	—	—	—	(672,162)	—	(672,162)
Balance at December 31, 2014	19,506,802	1,951	145,729	407,381	1,806,250	(867,362)	(1,069)	1,492,880
Stock based compensation	—	—	—	139,224	—	—	—	139,224
Common shares to be issued (Note 3)	—	—	—	—	40,000	—	—	40,000
Shares issued for services	1,812,500	181	1,806,069	—	(1,806,250)	—	—	—
Contribution of capital – interest	—	—	—	12,713	—	—	—	12,713
Contribution of capital – loan	—	—	—	90,000	—	—	—	90,000
Foreign currency translation adjustment	—	—	—	—	—	—	6,196	6,196
Net loss	—	—	—	—		(1,445,880)	—	(1,445,880)
Balance at December 31, 2015	21,319,302	2,132	1,951,798	649,318	40,000	(2,313,242)	5,127	335,133
Net loss	—	—	—	—		(262,716)	(2,296)	(265,012)
Balance at March 31, 2016	21,319,302	2,132	1,951,798	649,318	40,000	(2,575,958)	2,831	70,121

See accompanying notes to the consolidated financial statements

On October 16, 2015, the Company effectuated a 1 for 10 reverse stock split. Shares have been retroactively restated.

CTT Pharmaceutical Holdings, Inc.
Notes to Consolidated Financial Statements (unaudited)

NOTE 1 - BASIS OF PRESENTATION

The unaudited condensed consolidated interim financial statements of CTT Pharmaceutical Holdings, Inc. (Formerly, "Mindesta Inc."), (the "Company", or "Mindesta"), for the period ended March 31, 2016 and the notes thereto (the "Financial Statements") have been prepared in accordance with accounting principles generally accepted in the United States of America and have been presented in US dollars. The Financial Statements include the Company's wholly owned subsidiary CTT Pharmaceuticals Inc. ("CTT Pharma") (Note 2b). All significant intercompany accounts and transactions are eliminated in consolidation. The unaudited interim consolidated financial statements of the Company for the three month period ended March 31, 2016 and the notes thereto have been prepared in accordance with generally accepted accounting principles for interim financial information with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, the unaudited interim condensed consolidated financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of the Company's management, all adjustments (consisting of only normal accruals) considered necessary for a fair presentation have been included.

The Company specializes in the development of oral drug delivery systems for pain management and treatment. These condensed consolidated interim financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company has never generated cash flow from operations and is unlikely to generate cash flows from operations in the immediate or foreseeable future. For the period ended March 31, 2016, the Company has incurred a net loss before other items of $282,716 (2015 - $337,052), negative cash flows from operations of $193 (2015 - $39,652) and has had no sources of revenue. These factors raise substantial doubt regarding the ability of the Company to continue as a going concern. The Company's ability to continue as a going concern is dependent upon its ability to raise additional capital to pay expenses and carry out any further product development, market program, market acceptance of its products and achieving profitability. The Company will require significant financing to continue its operations and fund any further activities. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Company's fiscal period-end is December 31.

NOTE 2 – ORGANIZATION AND ACCOUNTING POLICIES

(a) Organization

Mindesta, Inc. was incorporated on November 6, 1996, as Winchester Mining Corporation in the State of Delaware. Effective July 26, 2011, the Company changed its name to "Mindesta Inc." The Company trades on the OTC under the symbol MDST.

(b) Reverse Acquisition and Recapitalization

On September 9, 2014, Mindesta entered into a Share Exchange Agreement (the "Exchange Agreement") with CTT Pharmaceuticals, Inc., f/k/a Fenwafe Inc., an entity organized under the Canadian Corporations Business Act in March 2007 and the shareholders of CTT Pharma whereby Mindesta acquired all of the issued and outstanding shares of common stock of CTT Pharma in consideration for the issuance of 14,918,329 shares of Mindesta common stock.

The 14,073,895 restricted shares of Mindesta common stock issued to former CTT Pharma stockholders and the 844,434 shares of Mindesta restricted shares issued at closing represent approximately 80% of the then issued and outstanding common stock of Mindesta.

As a result of the transactions effected by the Exchange Agreement, at closing CTT Pharma became a wholly owned subsidiary of Mindesta and Mindesta has abandoned all of its previous business operations with the business of CTT Pharma now being Mindesta's sole business. CTT Pharma is a development stage company with limited operations to date focused on developing an oral delivery system of medication contained on a disposable film.

The Exchange Agreement was accounted for as a reverse acquisition and recapitalization of the Company and as a result, the consolidated financial statements of the Company (the legal acquirer) are, in substance, those of CTT Pharma (the accounting acquirer), with the assets and liabilities, and expenses of the Company being included effective from the date of the Exchange Agreement. As the Exchange Agreement was accounted for as a reverse acquisition and recapitalization, there was no gain or loss recognized on the transaction. The transaction is in substance a capital transaction, rather than a business combination, thus no goodwill or other intangible assets have been recorded. The significant components of the transaction are as follows:

Assets acquired:	$	1,867
Liabilities assumed:		(31,767)
Net	$	(29,900)

The historical financial statements for periods prior to the Exchange Agreement are those of CTT Pharma, except that the equity section and earnings per share have been retroactively restated to reflect the Exchange Agreement. As a result of the Exchange Agreement, the Company has ceased mineral exploration and focuses on oral drug delivery systems (note 1).

(c) Significant Accounting Policies

i) Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an original or remaining maturity of less than three months at the date of purchase to be cash equivalents. Cash and cash equivalents include balances with banks and operating line of credit.

ii) Revenue Recognition

Revenue is recognized when persuasive evidence of an arrangement exists, title passes to the customer, typically upon delivery, and when collection of the fixed or determinable selling price is reasonably assured.

iii) Functional and Presentation Currency

The functional currency of CTT Pharma is the Canadian Dollar and the functional currency of Mindesta is the United States Dollar. The reporting currency is the United States Dollar. The financial statements of the CTT Pharma are translated to United States dollars in accordance with ASC 830 using period-end rates of exchange for assets and liabilities, and average rates of exchange for the period for revenues and expenses. Translation gains (losses) are recorded in accumulated other comprehensive income (loss) as a component of stockholders' equity.

iv) Comprehensive Income

Other comprehensive income refers to revenues, expenses, gains and losses that under generally accepted accounting principles are included in comprehensive income, but are excluded from net income as these amounts are recorded directly as an adjustment to stockholders' equity. Comprehensive income relates to the effects of translation from CTT Pharma's functional currency of the Canadian Dollar to the presentation currency of the United States Dollar.

v) Share Capital

Proceeds from share issuance net of share issuance costs are recorded at the amount paid. Share capital issued for non-monetary consideration is recorded at the fair market value of the shares on the date the shares are issued.

vi) Earnings Per Share

Basic earnings per share is computed using the weighted average number of common shares outstanding during the period, and diluted earnings per share is computed using the weighted average number of common shares outstanding during the period adjusted for all potentially dilutive common stock equivalents, except in cases where the effect of the common stock equivalents would be antidilutive. There were no potentially dilutive common stock equivalents outstanding at March 31, 2016 or 2015.

vii) Financial Instruments

The fair market value of the Company's financial instruments comprising cash, receivables, accounts payable and accrued liabilities and due to shareholder were estimated to approximate their carrying values due to immediate or short-term maturity of these financial instruments. The Company maintains cash balances at financial institutions which do not exceed federally insured amounts. The Company has not experienced any material losses in such accounts.

The Company is not exposed to any foreign exchange or interest rate risk.

viii) Fair Value of Financial Instruments

We measure and disclose certain financial assets and liabilities at fair value. ASC Topic 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC Topic 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.
Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

We utilize the active market approach to measure fair value for our financial assets and liabilities. We report separately each class of assets and liabilities measured at fair value on a recurring basis and include assets and liabilities that are disclosed but not recorded at fair value in the fair value hierarchy.

The fair values of cash, receivables, accounts payable and accrued liabilities, and due to shareholder for all periods presented approximate their respective carrying amounts due to the short term nature of these financial instruments.

ix) Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance so that the assets are recognized only to the extent that when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized.

Per FASB ASC 740 "Income taxes" under the liability method, it is the Company's policy to provide for uncertain tax positions and the related interest and penalties based upon management's assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. At December 31, 2014, the Company believes it has appropriately accounted for any unrecognized tax benefits. To the extent the Company prevails in matters for which a liability for an unrecognized benefit is established or is required to pay amounts in excess of the liability, the Company's effective tax rate in a given financial statement period may be affected. Interest and penalties associated with the Company's tax positions are recorded as Interest Expense.

x) Research Costs

Research costs are expensed in the year incurred. The Company expenses development costs in the year incurred, except when it is determined that the costs meet United States GAAP criteria for deferral and amortization. Deferred development costs, if any, will be amortized on straight-line basis over the expected useful life of the underlying product.

xi) Use of Estimates

The preparation of consolidated financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Significant estimates made by management in the accompanying financial statements include the valuation of deferred tax assets, valuation of stock based compensation including the assumptions and estimates incorporated in to the Black Scholes Option Pricing Model, and estimation of market rates of interest imputed on non-interest bearing shareholder loans.

(d)Recently Adopted and Future Accounting Pronouncements

i) ASU 2014-05

In March 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-05, "Foreign Currency Matters (Topic 830); Parents Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity." This guidance applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a business (other than a sale of substance real estate or conveyance of oil and gas, mineral rights) within a foreign entity. ASU No. 2014-05 is effective prospectively for fiscal periods (and interim reporting periods with those periods) beginning after December 15, 2014. The adoption of ASU 2014-05 did not have a material impact on our financial position or results of operations.

ii) ASU 2014-11

In July 2014, FASB issued ASU 2014-11, "Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or Tax Credit Carryforward Exits." The FASB's objective in issuing this ASU is to eliminate diversity in practice resulting from a lack of guidance on this topic in current U.S. GAAP. This ASU applies to all entities with unrecognized tax benefits that also have tax loss or tax credit carryforwards in the same tax jurisdiction as of the reporting date. ASU No. 2014-11 is effective for public entities for fiscal periods beginning after December 15, 2014, and interim periods within those periods. Early adoption is permitted. The amendments should be applied to all unrecognized tax benefits that exist as of the effective date. Entities may choose to apply the amendments retrospectively to each prior reporting period presented. The adoption of ASU 2014-05 did not have a material impact on our financial position or results of operations.

NOTE 2 – ORGANIZATION AND ACCOUNTING POLICIES (continued)

iii) ASU 2015-08

In April 2015, FASB issued ASU 2015-08, "Discontinued Operations". ASC guidance was issued related to discontinued operations which changed the criteria for determining which disposals can be presented as discontinued operations and modified related disclosure requirements. The updated guidance requires an entity to only classify discontinued operations due to a major strategic shift or a major effect on an entity's operations in the financial statements. The updated guidance will also require additional disclosures relating to discontinued operations. The update is effective prospectively for the Company's fiscal period beginning January 1, 2015. Early application is permitted. Adoption of ASU 2015-08 did not have an impact on our financial position or results of operations.

iv) ASU 2015-12

In September 2015, FASB issued ASU 2015-12, "Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period". ASC guidance was issued to update the guidance on performance stock awards. The guidance requires that a performance target that affects vesting and that could be achieved after the requisite service period is treated as a performance condition. This standard is effective for the Company's fiscal period beginning January 1, 2016. Early application is permitted. The Company does not expect the updated guidance to have a material impact on the consolidated financial position, results of operations or cash flows.

iv) ASU 2015-15

In August 2015, FASB issued ASU 2015-15, "Presentation of Financial Statements – Going Concern". ASC guidance was issued that explicitly requires management to assess an entity's ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. This standard is effective for the Company's fiscal period ending December 31, 2017, and for annual periods and interim periods thereafter. Early application is permitted. The Company does not expect the updated guidance to have a material impact on the consolidated financial position, results of operations or cash flows.

NOTE 3 – PREPAID EXPENSES

During the year ended December 31, 2014 the Company entered into various consulting agreements for services to be rendered over 1 to 2 periods. In consideration for the consultants' services the Company issued 1,812,500 common shares valued at $1,806,250 based on the closing stock price of the Company on the date of the agreements, and recorded this as prepaid expense. As at March 31, 2016, $1,194,604 had been expensed.

As at March 31, 2016 the Company was obligated to issue a further 100,000 common shares pursuant to a consulting agreement for services to be rendered over a period of one year. The Company has recorded this as a prepaid expense of $40,000 as at the date of the agreement calculated with reference to the number of common shares to be issued multiplied by the quoted stock price at September 30, 2015. Refer to Note 4D.

NOTE 4 – STOCKHOLDER'S EQUITY

A. COMMON STOCK

The number of common shares outstanding at March 31, 2016 and December 31, 2015 were as follows:

	Number	Par Value	Additional Paid-in Capital
Outstanding at March 31, 2016 and December 31, 2015	21,319,302	$ 2,132	$ 1,951,798

On October 1, 2014 the board of directors approved a resolution to increase the authorized capital of the Company from 200,000,000 common shares to 300,000,000 common shares.

B. STOCK OPTIONS

On October 17, 2014, the Company granted stock options to purchase 1,350,000 common shares at a price of $0.15 per share until December 31, 2017. Half of the options vested immediately with the remaining options vesting over a one period or two period term. The fair value of the option grant was estimated using the Black-Scholes option-pricing model with the following assumptions: expected volatility of 390% - 396%; risk-free interest rate of 1.10% - 1.44%; and an expected term of 3.21 periods.

There were 1,415,000 options outstanding and 965,000 exercisable at March 31, 2016 (2014 – 1,415,000 outstanding and 740,000 exercisable).

The Company recognized $nil in stock compensation expense for the period ending March 31, 2016 (2015 - $43,650).

C. EARNINGS PER SHARE

The basic and fully-diluted weighted average number of common shares outstanding was as follows:

For the 3 months ended:	
March 31, 2016	21,319,302
March 31, 2015	19,506,802

For the periods ended March 31, 2016 and 2015, the inclusion of common stock equivalents in the calculation of the weighted average number of shares is anti-dilutive.

D. COMMON SHARES TO BE ISSUED

As at March 31, 2016 the Company was obligated to issue a further 100,000 common shares pursuant to a consulting agreement for services to be rendered over a period of one year. The Company has recorded this as a prepaid expense of $40,000 as at the date of the agreement calculated with reference to the number of common shares to be issued multiplied by the quoted stock price at September 30, 2015.

The Company has not yet issued the common shares and as such has reflected this commitment to issue fully vested non-forfeitable common shares as common shares to be issued.

NOTE 5 – RELATED PARTY TRANSACTIONS

	As at	
	March 31 2016	December 31 2015
Due to shareholders	$ 88,032	$ 87,082
Due to related party	-	-
	$ 88,032	$ 87,082

The Company has recorded obligations to its shareholders that are non-interest bearing or bear interest rates below equivalent market rates. During the year ended December 31, 2015, the Company has recorded additional interest expense of $12,713 (2014 - $7,958) to reflect the benefit received from the shareholder for these non-interest bearing or low interest loans, using an estimated market rate of interest of 20%.

Included in due to related parties is a balance of $Nil related to management fees payable to the Company's President (December 31, 2014 - $60,000). During 2015, the President forgave the balance of management fees payable to him of $90,000. This forgiveness of debt was recorded as a contribution to capital.

NOTE 6 – COMMITMENTS AND CONTINGENCIES

The Company has been named in a lawsuit filed by Windale Properties in the amount of CDN$19,781. The claim is the result of termination of leased premises in Oakville, Ontario prior to expiry of the lease. In 2009 a judgment of CDN$24,908 with annual interest of 3% was issued against the Company. No amount has been accrued as no action has been undertaken since 2009 to enforce the judgment.

NOTE 7 – INCOME TAXES

As at December 31, 2015, the Company's net operating loss carry forward benefit has been fully offset by a valuation allowance based on management's determination that it is not more likely than not that some or all of this benefit will be realized. These losses expire in 2035.

Accounting for uncertainty for Income Tax

Effective January 1, 2009, we adopted the interpretation for accounting for uncertainty in income taxes which was an interpretation of the accounting standard accounting for income taxes. This interpretation created a single model to address accounting for uncertainty in tax positions. This interpretation clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements.

NOTE 8 – RESTATEMENT OF CONSOLIDATED FINANCIAL STATEMENTS

The Company determined that there had been an error in its accounting for common shares to be issued for services contained in its consolidated financial statements for the year ended December 31, 2014 filed with the Securities Exchange Commission on April 10, 2015. The Company determined that the common shares to be issued for services should have been presented in stockholders' equity instead as a liability, as the contracts granted a fully vested, non-forfeitable right to common shares as at the date of the contracts. A restatement adjustment was made to correct the error by increasing Common shares to be issued by $1,806,250, decreasing Liability to issue common shares by $906,250, and decreasing Gain on contracts settled through shares by $900,000.

As noted above there was a stock split announced which requires a retro-active adjustment. This has also been reflected in the restated consolidated financial statements for both current period as well as the comparative figures.

The following table sets forth the effects of the restatement adjustments discussed above on the Consolidated Balance Sheet as at June 30, 2015.

	Previously Reported	Increase (Decrease)	Restated
	$	$	$
Liabilities			
Liability to issue common shares	40,000	(40,000)	—
Total liabilities	196,373	(40,000)	156,373
Stockholders' equity (deficiency)			
Par Value	21,320	(19,188)	2,132
Additional paid in capital	1,032,610	919,188	1,951,798
Common shares to be issued	—	40,000	40,000
Deficit	(667,071)	(900,000)	(1,567,071)
Total stockholders' equity (deficiency)	986,887	40,000	1,026,887

The following table sets forth the effects of the restatement adjustments discussed above on the Consolidated Statement of Stockholders' Equity as at June 30, 2015.

	Previously Reported	Increase (Decrease)	Restated
	$	$	$
Common shares to be issued	—	40,000	40,000
Par Value	21,320	(19,188)	2,132
Additional paid in capital	1,032,610	919,188	1,951,798
Accumulated deficit	(667,071)	(900,000)	(1,567,071)
Total stockholders' equity (deficit)	986,887	40,000	1,026,887